Literature DB >> 21149914

HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.

Rainer Weber, Caroline Sabin, Peter Reiss, Stephane de Wit, Signe W Worm, Matthew Law, Francois Dabis, Antonella D'Arminio Monforte, Eric Fontas, Wafaa El-Sadr, Ole Kirk, Martin Rickenbach, Andrew Phillips, Bruno Ledergerber, Jens Lundgren.   

Abstract

BACKGROUND: Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals.
METHODS: The prospective observational database of the D:A:D collaboration of 11 cohorts of HIV-infected individuals, including 212 clinics in Europe, the United States and Australia was used. Multivariate Poisson regression was used to assess the effect of HCV or HBV infection on the development of myocardial infarction after adjustment for potential confounders, including cardiovascular risk factors, diabetes mellitus and exposure to antiretroviral therapy.
RESULTS: Of 33,347 individuals, 517 developed a myocardial infarction over 157,912 person-years, with an event rate of 3.3 events/1,000 person-years (95% confidence interval [CI] 3.0-3.6). Event rates (95% CIs) per 1,000 person-years in those who were HCV-seronegative and HCV-seropositive were 3.3 (3.0-3.7) and 2.7 (2.2-3.3), respectively, and for those who were HBV-seronegative, had inactive infection or had active infection were 3.2 (2.8-3.5), 4.2 (3.1-5.2) and 2.8 (1.8-3.9), respectively. After adjustment, there was no association between HCV seropositivity (rate ratio 0.86 [95% CI 0.62-1.19]), inactive HBV infection (rate ratio 1.07 [95% CI 0.79-1.43]) or active HBV infection (rate ratio 0.78 [95% CI 0.52-1.15]) and the development of myocardial infarction.
CONCLUSIONS: We found no association between HBV or HCV coinfection and the development of myocardial infarction among HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21149914     DOI: 10.3851/IMP1681

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  21 in total

Review 1.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

2.  Short communication: risk of elevated total cholesterol/high-density lipoprotein cholesterol ratio after antiretroviral therapy in HIV/hepatitis C virus patients.

Authors:  Lisa Kakinami; Michael J Adams; Robert C Block; Susan E Cohn; Benedict Maliakkal; Susan G Fisher
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-10       Impact factor: 2.205

3.  Effect of hepatitis C virus infection on the right ventricular functions, pulmonary arterypressure and pulmonary vascular resistance.

Authors:  Canan Demir; Mehmet Demir
Journal:  Int J Clin Exp Med       Date:  2014-08-15

Review 4.  Cardiovascular disease and HIV infection.

Authors:  Virginia A Triant
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

5.  Impact of hepatitis coinfection on hospitalization rates and causes in a multicenter cohort of persons living with HIV.

Authors:  Trevor A Crowell; Kelly A Gebo; Ashwin Balagopal; John A Fleishman; Allison L Agwu; Stephen A Berry
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

Review 6.  Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

Authors:  Roger Bedimo; Oladapo Abodunde
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

7.  Impact of hepatitis coinfection on healthcare utilization among persons living with HIV.

Authors:  Trevor A Crowell; Stephen A Berry; John A Fleishman; Richard W LaRue; Philip T Korthuis; Ank E Nijhawan; Richard D Moore; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

8.  HIV, Cocaine Use, and Hepatitis C Virus: A Triad of Nontraditional Risk Factors for Subclinical Cardiovascular Disease.

Authors:  Gregory M Lucas; Mohamed G Atta; Derek M Fine; Allison M McFall; Michelle M Estrella; Katie Zook; James H Stein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-09-08       Impact factor: 8.311

Review 9.  Lipids and HCV.

Authors:  M F Bassendine; D A Sheridan; S H Bridge; D J Felmlee; R D G Neely
Journal:  Semin Immunopathol       Date:  2012-10-31       Impact factor: 9.623

Review 10.  Cardiovascular disease risk in an aging HIV population: not just a question of biology.

Authors:  Kaku So-Armah; Matthew S Freiberg
Journal:  Curr Opin HIV AIDS       Date:  2014-07       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.